Early evidence was indirectly provided by epidemiological and laboratory studies, which revealed that cyclooxygenase-2 (COX-2) inhibitors are capable of suppressing the incidence of colorectal and breast cancer (1–3). This evidence concerns the gene PTGS2 and breast carcinoma.